Abstract. Cardiovascular disease is responsible for one of the highest rates of fatality worldwide. The present study investigated the presence and influence of microRNA (miRNA)-23a in the regulation of acute myocardial infarction (AMI). A total of 6 patients with AMI and 6 normal volunteers without myocardial disease were included, and blood samples were taken to analyze the expression of miRNA-23a by reverse transcription-quantitative polymerase chain reaction. miRNA-23a expression in patients with AMI was downregulated compared with the normal group. In H9C2 cells treated with \( \text{H}_2\text{O}_2 \), upregulation of miRNA-23a expression increased the superoxide dismutase, glutathione and catalase activity levels, and suppressed the malonaldehyde activity level, as determined by ELISA. Western blot analysis and a caspase-3 substrate assay demonstrated that upregulation of miRNA-23a expression suppressed the Bcl-2-associated X (Bax)/Bcl-2 protein expression ratio, caspase-3 activity level and tumor suppressor p53 (p53) protein expression in \( \text{H}_2\text{O}_2 \)-induced H9C2 cells. Furthermore, downregulation of phosphatase and tensin homolog (PTEN), by the PTEN inhibitor bpV(HOpic), increased miRNA-23a expression and suppressed the Bax/Bcl-2 protein expression ratio, caspase-3 activity level and p53 protein expression in \( \text{H}_2\text{O}_2 \)-induced H9C2 cells. Therefore, the results of the present study indicate that the expression of miRNA-23a may regulate AMI through targeting PTEN in patients and in vitro, and PTEN/miRNA-23a may therefore be potential targets for the clinical treatment of AMI.

Introduction

Cardiovascular disease is one of the diseases with the highest fatality rates worldwide. In the United States, ~1/6th of the annual death toll is associated with coronary heart disease and associated diseases with myocardial injury (1). Acute myocardial infarction (AMI) results in ventricular remodeling that causes the deterioration of heart function leading to heart failure (2). Myocardial fibrosis leads to decreased myocardial contractility and subsequent ventricular systolic dysfunction (3).

Myocardial remodeling, including the remodeling of myocardial cells and the extracellular matrix (ECM), is key for the transformation process of heart disease to heart failure (4). Previously, it was hypothesized that the function of the ECM is constant and is primarily responsible for connection, support and protection (5). Recently, a study demonstrated that ECM is in an active state and is actively involved in intracellular and extracellular signaling and the maintenance of cardiac structure and function (5). Therefore, ECM remodeling serves an important role in the initiation and development of heart failure.

AMI is a cardiovascular disease with serious implications for human health. It may lead to heart failure and a number of other conditions with poor prognoses (6). Myocardial fibrosis is an important pathophysiological alteration following AMI. It is activated as a result of multiple fibrosis-associated factors and leads to interstitial cell hyperplasia (7). Myocardial fibrosis increases cardiac stiffness, decreases diastolic systolic function and alters the normal structure of cardiac electrophysiology, which leads to arrhythmia and potentially even sudden death (8).

Phosphatase and tensin homolog (PTEN) is a tumor suppressor that was discovered in 1997. The genes that encode PTEN are located at 10q23.3 and encoded by a dual specificity phosphatase consisting of 403 amino acids (9). PTEN is a dual specificity phosphatase with lipid phosphatase and protein phosphatase activity (9). PTEN enables the secondary messenger produced by phosphatidylinositol 3-kinase (PI3K) to phosphorylate and prevent protein kinase B (Akt) from being activated and inhibits its downstream biological functions (10). It has been reported that PTEN is associated with ischemic heart disease (11). Blocking the
PTEN signaling pathway confirmed that PTEN influences myocardial ischemic injury events and reduces the death of myocardial cells (11). However, studies on myocardial ischemic injury in which one or several genes that regulate cardiomyocyte apoptosis through PTEN are investigated have not previously been performed (11).

MicroRNAs (miRNAs) are a group of non-coding RNAs that are endogenous, short (~22 bp) (12) and are highly conserved in sequence between species. Currently, there are ~1,400 types of miRNAs in humans and novel miRNA are frequently identified. Each type of miRNA serves an important role in the transcription processes in the body by regulating the expression of various target genes (13). miRNA influences cells in numerous ways, including the regulation of cellular apoptosis and necrosis, and these two mechanisms are of great importance in ventricular remodeling during the developmental phase of AMI. The results of the present study help to elucidate the presence and role of miRNA-23a in the regulation of AMI.

Materials and methods

Patient selection and blood collection. The present study was approved by the Regional Ethics Committee of Beijing Chaoyang Hospital (Beijing, China) and all patients involved gave their written informed consent. A total of 6 patients with AMI (aged 57-66 years, male) and 6 normal volunteers (aged 23-28 years, male) without myocardial disease were recruited between July 2015 and August 2015 from the Department of Internal Medicine, Beijing Chaoyang Hospital. Between 8:00 and 10:00 a.m., blood samples (5 ml) were collected and centrifuged at 2,000 x g for 10 min at 4˚C to be stored at -80˚C.

Cell culture. The H9C2 cell line was purchased from the Type Culture Collection of Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco's modified Eagle medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Beyotime Institute of Biotechnology, Haimen, China) in a humidified atmosphere containing 5% CO2 at 37˚C.

Cell transfection. The miRNA-23a mimic (5'-ggc cgg ctg gggttctggg-3') and the negative controls (5'-CCCCCCCCCCC C-3') were purchased from MyGenostics, Inc., (Beijing, China). Following 6 h of incubation at 37˚C with Dulbecco's modified Eagle medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% fetal bovine serum (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA), 100 U/ml penicillin and 100 µg/ml streptomycin (Beyotime Institute of Biotechnology, Haimen, China) in a humidified atmosphere containing 5% CO2 at 37˚C.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from blood samples or cell samples using TRIzol™ reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA (0.5-1 µg) was reverse transcribed into cDNA using an iScript™ cDNA synthesis kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at 37˚C for 60 min and 85˚C for 5 min. qPCR was performed using Takara SYBR Premix Ex Taq™ (Tli RNase H Plus; TakaraBio, Inc., Otsu, Japan) on a CFX96™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.) with the following thermocycling conditions: 95˚C for 10 min, followed by 40 cycles of 95˚C for 25 sec, 60˚C for 30 sec and 72˚C for 30 sec. The primers used for qPCR were as follows: miR-23a forward, 5'-GGGGGGG GATCACAATTGCCA-3' and reverse, 5'-CAGTGACGGGTC CGAGGTT-3'; and U6 forward, 5'-GCTTCGACGACCAT ATACTAAAAT and reverse, 5'-CGTTCACGAATTTG CGTGTCAT-3'. The relative expression level of miRNA-23a was calculated by the 2-ΔΔCq method (14).

Measurement of oxidative stress. H9C2 cells (1x105 cells) transfected with miRNA-23a or negative controls were treated with 600 µM H2O2 with or without 1 µM bpV(Ohp) for 2 h. Subsequently, H9C2 cells were lysed in radioimmunoprecipitation buffer (RIPA; Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) containing phenylmethylsulfonyl fluoride (PMSF; 1:100; Nanjing KeyGen Biotech Co., Ltd.). Total proteins were quantified with a bicinchoninic assay (BCA) protein kit (Beyotime Institute of Biotechnology). Total protein (10-20 µg) was incubated with superoxide dismutase (SOD, cat. no. A001-3), glutathione (GSH; cat. no. A006-2), catalase (CAT; cat. no. A007-1-1) and malondialdehyde (MDA, cat. no. A003-1) ELISA kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Absorbance was measured at 450 nm.

Measurement of caspase-3 activity level. H9C2 cells (1x105 cells) transfected with miRNA-23a or negative controls were treated with 600 µM H2O2 with or without 1 µM bpV(Ohp) for 2 h. Subsequently, H9C2 cells were lysed in RIPA buffer containing PMSF (1:100). Total proteins were quantified with a BCA protein assay kit. A total of 10 µg total protein was incubated with the caspase-3 substrate Ac-DEVD-pNA (2 mM; Beyotime Institute of Biotechnology) for 2 h at 37˚C. Absorbance was measured at 405 nm.

Western blot analysis. H9C2 cells (1x106 cells) transfected with miRNA-23a or negative controls were treated with 600 µM H2O2 with or without 1 µM bpV(Ohp) for 2 h. Subsequently, H9C2 cells were lysed in RIPA buffer containing PMSF (1:100). Total proteins were quantified with a BCA protein assay kit. A total of 50-60 µg total protein was subjected to 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Bio-Rad Laboratories, Inc.). Membranes were blocked with 5% non-fat milk for 1 h at 37˚C and then probed with primary antibodies against Bcl-2-associated X (Bax; cat. no. A2211; 1:2,000; AbCerol Biotech Co., Ltd., Woburn, MA, USA), Bcl-2 (cat. no. A0208; 1:2,000; AbCerol Biotech Co., Ltd.), tumor suppressor p53 (p53; cat. no. AP0464; 1:1,000; AbCerol Biotech Co., Ltd.) and GAPDH (cat. no. A0080; 1:2,000; AbCerol Biotech Co., Ltd.) overnight at 4˚C.
Following incubation with horseradish peroxidase-conjugated goat anti-rabbit IgG antibodies (1:10,000; cat. no. HSA0003; Shanghai Bioon Biotechnology Co., Ltd., Shanghai, China) and anti-mouse secondary antibodies (1:5,000; cat. no. sc-2020; Santa Cruz Biotechnology, Inc.) for 1 h at room temperature, Clarity Max™ Western ECL Substrate (cat. no. 1705062; Bio-Rad Laboratories, Inc.) was used for visualization. Protein bands were visualized using Image-ProPlus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

**Statistical analysis.** The results are presented as the mean ± standard deviation. All data were analyzed with an independent-samples Student t-test or one-way analysis of variance test followed by Bonferroni’s tests using SPSS software (version 17.0; SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Expression of miRNA-23a in patients with AMI.** miRNA-23a expression was analyzed in patients with AMI and healthy volunteers. The results of RT-qPCR demonstrated that miRNA-23a expression in patients with AMI was significantly downregulated compared with the healthy volunteer group (P<0.01; Fig. 1).

**Expression of miRNA-23a in vitro in AMI.** In addition, the miRNA-23a mimic was transfected into H9C2 cells, which promoted miRNA-23a expression in H9C2 cells. Transfection of the miRNA-23a mimic in H2O2-treated H9C2 cells significantly increased the expression of miRNA-23a, compared with the negative control group (P<0.01; Fig. 2).

**Effect of miRNA-23a expression on oxidative stress in vitro in AMI.** To investigate the functional effect of miRNA-23a in H9C2 cells treated with H2O2, ELISAs were conducted to analyze levels of oxidative stress markers. There was a significant increase in the activity of SOD, GSH and CAT, and a decrease of MDA content, compared with miRNA-23a-overexpressing H9C2 cells treated with H2O2 alone (P<0.01; Fig. 3).

**Effect of miRNA-23a expression on apoptosis in vitro in AMI.** To investigate the functional effect of miRNA-23a on apoptosis in H9C2 cells treated with H2O2, ELISA kit was employed to analyze caspase-3 activity. As demonstrated in Fig. 4A, in the miRNA-23a-overexpressing H9C2 cells treated with H2O2, the caspase-3 activity was significantly decreased compared with the negative control group. In addition, the Bax/Bcl-2 and p53 protein expression was significantly decreased in miRNA-23a-overexpressing H9C2 cells treated with H2O2 compared with the negative control group (P<0.01; Fig. 4B-D).

**PTEN inhibitor effect on the in vitro expression of miRNA-23a in AMI.** In order to investigate the association between miRNA-23a and PTEN expression in AMI, the PTEN inhibitor bpV(HO)pic was added to miRNA-23a-overexpressing H9C2 cells. In the miRNA-23a-overexpressing H9C2 cells treated with H2O2, the PTEN inhibitor significantly increased miRNA-23a expression, compared with the miRNA-23a-overexpressing group alone (P<0.01; Fig. 5).

**Effect of PTEN inhibitor on in vitro oxidative stress in AMI.** In order to investigate the effect of PTEN on oxidative stress in vitro in AMI, miRNA-23a-overexpressing H9C2 cells were treated with H2O2. There was a significant increase in the activities of SOD, GSH and CAT, and a decrease of MDA content, compared with miRNA-23a-overexpressing H9C2 cells treated with H2O2 alone (P<0.01; Fig. 6).

**Effect of PTEN inhibitor on apoptosis in AMI.** The effect of PTEN on in vitro on apoptosis in AMI was investigated. As demonstrated in Fig. 7, the downregulation of PTEN significantly suppressed Bax/Bcl-2 and p53 protein expression, and caspase-3 activity level, in miRNA-23a-overexpressing H9C2 cells treated with H2O2, compared with the miRNA-23a-overexpressing H9C2 cells treated with H2O2 alone (P<0.01).

**Discussion**

With rapid socioeconomic development and improvements in living standards, and the alteration of modern lifestyles, the incidence of cardiovascular and cerebrovascular disease is increasing (15). The high morbidity rate and high case-fatality rate have serious effects on the physical and mental health of individuals (16). In China, the case-fatality rate of cardio-cerebral vascular diseases is the second largest following malignant tumors (17). Solutions to the relevant problems are urgently required, such as methods that allow more in-depth research into the pathogenesis of cardiovascular and cerebrovascular diseases, and the development of more effective and safer clinical drugs (18).

Apoptosis is a form of programmed cell death. In the acute period of myocardial infarction, apoptosis is involved in...
the death of myocardial cells. It is similar to that myocardial has lost its improvement process in subacute or stale stage of myocardial infarction. miRNAs influence the regulation of cellular apoptosis and necrosis, and these two mechanisms are essential for the ventricular remodeling during the developmental phase of AMI (12). It has been demonstrated that there are numerous alterations in the expression of miRNAs in blood samples during the acute stage of AMI (19). If the association between miRNA expression and AMI could be elucidated, molecular markers may be identified for early clinical diagnosis of AMI to improve the survival rate of patients with AMI (20). Therefore, a number of studies in

Figure 3. Effect of miRNA-23a expression on oxidative stress in an in vitro model of AMI. The effect of the expression of miRNA-23a on (A) CAT, (B) GSH and (C) SOD activity levels, and (D) MDA levels, in an in vitro model of AMI. **P<0.01 vs. negative control group. miRNA, microRNA; AMI, acute myocardial infarction; CAT, catalase; GSH, glutathione; SOD, superoxide dismutase; MDA, malondialdehyde.

Figure 4. Effect of miRNA-23a expression on apoptosis in an in vitro model of AMI. (A) Quantitative analysis of the effect of miRNA-23a expression on caspase-3 activity in an in vitro model of AMI. Densitometric and statistical analysis of (B) Bax/Bcl-2 protein expression ratio and (C) p53 protein expression. (D) Representative western blot images for Bax, Bcl-2 and p53 protein expression in an in vitro model of AMI. **P<0.01 vs. negative control group. miRNA, microRNA; AMI, acute myocardial infarction; Bax, Bcl-2-associated X; p53, tumor suppressor p53.

Figure 5. PTEN inhibitor effects on the miRNA-23a expression in an in vitro model of acute myocardial infarction. **P<0.01 vs. negative control group; **P<0.01 vs. miRNA-23a group. PTEN, phosphatase and tensin homolog; miRNA, microRNA.
China and worldwide have been initiated using clinical and animal experimental models. In the present study, miRNA-23a expression in patients with AMI was demonstrated to be downregulated compared with the healthy volunteer group. Mao et al. (21) identified miRNA-23a as being involved in tumor necrosis factor-α-induced protection of bone marrow-derived mesenchymal stem cell apoptosis through regulating caspase-7 and myocardial infarction.

A previous study demonstrated that oxidative stress is a common mechanism of various factors that cause cardiovascular injury (22). During the pathological process of a number of cardiovascular diseases, including atherosclerosis, hypertension, ischemic heart disease and hyperlipidemia, excessive oxygen free radical production and suppression of the antioxidant defense mechanism for managing free radicals has been observed (22). Previously, attention has focused on the influence of reactive oxygen species (including oxygen free radicals) on cardiac and vascular function. White blood cells produce reactive oxygen species, which cause vascular injury in AMI (23). White blood cells have the ability to release high
PTEN regulates developmental malformations and abnormal migration and invasion in osteosarcoma cells through downregulation of PTEN expression. In the present study, the PTEN inhibitor was observed to increase miRNA-23a expression in H9C2 cells treated with H2O2. Zhao et al. (25) demonstrated that miRNA-23a-3p attenuated injury caused by oxidative stress in focal cerebral ischemia-reperfusion mice. miRNA-23a-3p inhibits the infarction factors that kill the myocardial cells of rats, including the expression of p53, Bax and tumor necrosis factor receptor superfamily member 6 (Fas). Cytochrome C is released and forms an apoptotic body by combining with caspase-9 (26). Subsequently, apoptosis is induced in cells with activated caspase-3 through downstream signaling pathways (27). Studies have demonstrated that caspase-3 and caspase-9 proteases effectively inhibited the apoptosis of cardiac muscle cells by decreasing the activity and expression of caspase-3/9 (28). The Bcl-2 family is reported to affect the release of cytochrome C through mitochondrial channels, inhibit the release of Bax and inhibit the activation of cytochrome C-induced apoptosis. Therefore, Bcl-2 acts as an inhibitor of apoptosis (26).

Fluctuations in the intracellular content of Bcl-2 can induce a pro-apoptotic signaling cascade (29). Bcl-2 family members are among the most important membrane protein molecules in apoptosis and control cell apoptosis by internal and external signals in different cells (29). A number of studies have demonstrated that certain genes promote apoptosis (such as Bax, p53 and Fas), while other genes are able to inhibit apoptosis (such as Bcl-2) (30). The in vivo ratio between proapoptotic proteins and inhibitory proteins is key for determining the fate of cells (29). For instance, when Bcl-2 protein expression is higher than Bax protein expression, cell survival is promoted. By contrast, when Bax protein levels are higher compared with Bcl-2 levels, apoptosis is accelerated (26). Therefore, the results of the present study demonstrated that overexpression of miRNA-23a decreased caspase-3 activity, Bax/Bcl-2 ratio and p53 protein expression in H9C2 cells treated with H2O2. Wang et al. (31) revealed that berberine induced tumor apoptosis through upregulation of p53 by miRNA-23a in hepatocellular carcinoma. Wang et al. (32) also reported that glucagon like peptide-1 reduced apoptosis and Bax expression by downregulating miRNA-23a.

PTEN is a non-secreted protein inherently expressed in cells. It also exists in the nucleus, cytoplasm and membrane (10). It is involved in multiple signal transduction pathways within a cell, including those associated with cell division, proliferation, differentiation, migration and extracellular matrix metabolism, and other physiological and pathological processes (9). In the present study, the PTEN inhibitor was observed to increase miRNA-23a expression in H9C2 cells treated with H2O2. Tian et al. (33) demonstrated that miRNA-23a enhanced migration and invasion in osteosarcoma cells through downregulation of PTEN expression.

PTEN also serves an important role in growth (9). In addition, PTEN regulates developmental malformations and abnormal differentiation in the third germ layer (34). Investigation of the effect of PTEN on heart growth and function in adult mice with a specific knockout of PTEN in cardiac muscle cells demonstrated that muscular hypertrophy caused by external pressure may be inhibited by knocking out PTEN, which therefore protects the heart functions (35). In the present study, the downregulation of PTEN was observed to suppress p53 protein expression in miRNA-23a-overexpressing H9C2 cells treated with H2O2.

In summary, the present study has confirmed that the expression of miRNA-23a may regulate AMI-induced apoptosis in patients with AMI and an in vitro model, which may occur via inhibition of caspase-3, Bax/Bcl-2 and p53 expression through targeting PTEN. The results of the present study indicate that PTEN/miRNA-23a may be potential therapeutic targets for treating AMI-induced apoptosis in a clinical setting.

Acknowledgements
Not applicable.

Funding
The present study was supported by the National Natural Science Foundation of China (grant no. 81560368).

Availability of data and materials
The analysed data sets generated during the study are available from the corresponding author on reasonable request.

Authors’ contributions
QS designed the study; SL and JR performed the experiments; QS analyzed the data; QS wrote the manuscript.

Ethics approval and consent to participate
The present study was approved by the Regional Ethics Committee of Beijing Chaoyang Hospital (Beijing, China) and all patients involved provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References


